

4DMEDICAL RECEIVES US\$600K PURCHASE ORDER FOR A PRECLINICAL SCANNER FROM UNIVERSITY OF MICHIGAN

Highlights

- 4DMedical will deploy its XV Technology™ at University of Michigan in the U.S. after receiving a purchase order to sell a Permetium™ preclinical scanner
 - 4DMedical's Permetium preclinical scanner, developed from the Company's early R&D activities, is designed to assist with research and validation of XV Technology at opinion-leading medical institutions
 - University of Michigan will use the preclinical scanner in its Center for Molecular Imaging to perform safe and quick quantitative imaging of lung function and vascular changes
 - The Company will receive a total of US\$600,000 for the sale of the Permetium preclinical scanner and scan package which will utilise 4DMedical's proprietary software to analyse respiratory data
 - 4DMedical remains focused on the commercialisation of its software technology via the integration with existing hospital X-ray infrastructure
-

17 June 2021: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce that its XV Technology™ will be deployed at University of Michigan in the U.S. after the Company received a purchase order for one of its Permetium™ preclinical scanners.

The Permetium preclinical scanner will be installed and used by the University of Michigan Center for Molecular Imaging to perform safe and quick quantitative imaging of lung function and vascular changes. The Permetium preclinical scanner is a valuable tool for cardiothoracic translational research, which includes evaluation of novel classes of drugs focused on treatment of cardiothoracic diseases, and can be used to assist in deciphering lung airway disease.

The Company will receive US\$600,000 from the sale of the scanner to be funded by the U.S. National Institutes of Health (NIH), a U.S. government agency responsible for biomedical and public health research. The sale price includes the use of 4DMedical's proprietary software to analyse respiratory scans generated from the preclinical scanner – additional scans required will generate software-as-a-service (SaaS) revenue for 4DMedical. The scanner has been manufactured and is expected to be shipped to the University of Michigan within the coming months.

4DMedical Founder and CEO Andreas Fouras said:

"We are very pleased to support the University of Michigan's activities with our XV Technology and preclinical scanner. This provides the organisation with the only commercially available device for ultra-high-resolution imaging and quantification of cardiothoracic disease models. The sale of preclinical scanners and XV Technology software to opinion-leading sites will provide further evidence of the effectiveness of our technology and help drive clinical demand for 4DMedical's software products."

As detailed in the Company's Prospectus released 7 August 2020, the preclinical scanner was developed from 4DMedical's early R&D activities and is expected to make up a small proportion of overall revenue in the short-to-medium term. The Company anticipates that the significant majority of future revenue will be

generated from its software products, such as XV Lung Ventilation Analysis Software (XV LVAS™), as commercialisation accelerates in the U.S. and Australia.

ENDS

Authorised by the 4DMedical Board of Directors.

Contacts:

Corporate

Charlene Stahr

Company Secretary

companysecretary@4dmedical.com

Investor

Simon Hinsley

+ 61 401 809 653

shinsley@4dmedical.com

Media

Matthew Wright

+ 61 451 896 420

matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.